{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0050996289","value":"0.0030201667"}]}],"title":"Pre Conventional dendritic cells type 1 (Cycle 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1900236337","value":"0.152785"}]}],"title":"Pre Conventional dendritic cells type 2 (Cycle 2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1795932594","value":"0.1246616667"}]}],"title":"Pre Plasmacytoid dendritic cells (Cycle 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0054418615","value":"0.0038176667"}]}],"title":"Post Conventional dendritic cells type 1 (Cycle1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1900236337","value":"0.1421666667"}]}],"title":"Post Conventional dendritic cells type 2 (Cycle 2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1795932594","value":"0.0837116667"}]}],"title":"Post Plasmacytoid dendritic cells (Cycle 2)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Descriptive statistics will be used to evaluate the Immune cell profile in the peripheral blood and bone marrow following combination therapy using mass cytometry.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.\n\nDEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given intracutaneously\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nNivolumab: Given IV\n\nPoly ICLC: Given SC\n\nThe study originally provided for the possibility of dose de-escalation for the treatment arms, but as we had no dose limiting toxicities, the dose level 1 was declared the maximum administered dose and all patients were enrolled and treated at dose level 1.","id":"OG000","title":"Treatment (CDX-1401, Poly ICLC, Decitabine, Nivolumab)"}],"paramType":"MEAN","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"Up to 180 days","title":"Immune Cell Profile","type":"SECONDARY","unitOfMeasure":"percentage of CD45⁺ leukocytes"}